Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib with Postoperative RT in Triple Negative Breast Cancer (UNITY)
NCT03945721Phase 1Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2019
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of niraparib in triple-negative breast cancer (TNBC), sponsored by Massachusetts General Hospital. Primary endpoint: Maximum Tolerated Dose at 10 weeks. Started Jul 2019; status: active, not recruiting.
02
Drugs
niraparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03945721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03945721.